New Survey Showed GI Health and Anti-Aging Benefits of Morinaga's Probiotics Milk with BB536
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), Japanese leading dairy product company, today unveiled the results of a nationwide survey jointly conducted with Tokyo Healthcare University in Japan on the health status of over 20,000 middle-aged to elderly men and women for the purpose of investigating the relationship between regular consumption of calcium-fortified milk containing Bifidobacterium longum BB536 and health status.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151119005020/en/
The results reveal that subjects regularly consuming the probiotic milk were less likely to experience fractures and several diseases, and showed improvement in forgetfulness, quality of life in daily living, which supports the benefits of B. longum BB536 for anti-aging.
“The results obtained from this survey linked the continuous consumption of the probiotic milk supplemented with B. longum BB536 for reducing some disease risks, such as colon cancer, and in helping to prevent certain aging-related challenges of middle-aged to elderly people, in such areas as forgetfulness for example,” stated Dr. Taeko Shimoda, professor of Tenshi College, professor emeritus of Tokyo Healthcare University.
“Although other components in the milk, such as calcium, might have also contributed to the outcomes of the present survey, B. longum BB536 is believed to possess an important function from a point of view of improving intestinal health and the relationship with the gut-brain axis.”
The Survey Shows the Potential of Probiotic Milk Consumption for Anti-Aging
Questionnaires were distributed to middle-aged to elderly men and women aged in their 50s to 80s with or without experience of consuming “calcium fortified milk containing BB536,” from December 2013 to March 2014. A total of 92,110 questionnaires were distributed and 23,188 effective answers were received. Data analysis was performed by comparison between subjects with experience of the probiotic milk consumption for ≥ 3 years and for ≥4 times per week and subjects without experience of consumption of this probiotic milk.
Compared with the non-intake group, the probiotic milk-consuming group (intake group) showed the following;
- The proportions of subjects who had (a tendency to) constipation were lower in both men and women.
- The proportions of subjects who experienced forgetfulness (men and women), fatigue (women) and low back pain (women) in daily life were lower.
- The proportions of subjects who experienced colon polyp (men), kidney disease (women), liver disease (men) and gallstones (men) were lower.
- For women who had consumed the milk for over 10 years, fewer subjects experienced bone fractures in the past 5 years.
Risk for experiencing forgetfulness in daily life (Fig.1)
The result showed that there was a significant reduction of risk for forgetfulness by 19% (P = 0.03) and 14% (P = 0.002) for men and women, respectively, in the intake group compared to non-intake group.
B. longum BB536 (ATCC BAA-999) has been reported to be effective in normalizing anxiety-like behavior and hippocampal brain derived neurotrophic factor in mice with infectious colitis (Bercik et al., 2011). The present survey supported the possible effect of consumption of BB536 supplemented milk for improving brain health via the gut-brain axis.
Risk for developing a colon polyp
There was a significant reduction of risk for history development of a colon polyp by 26% (P = 0.003) for men in the intake group compared to non-intake group. B. longum BB536 has shown its effect in suppressing the development of carcinogenesis induced by carcinogen in male and female rats (Reddy and Rivenson,1993). In addition, intake of yogurt containing B. longum BB536 lowered the cell number of enterotoxigenic Bacteroides fragilis (ETBF), a bacteria which has been suggested to be associated with diarrheal disease, inflammatory bowel disease and colorectal cancer (Odamaki et al., 2012). The present survey suggests the possible effect of consumption of the probiotic milk supplemented with B. longum BB536 in lowering the risk of colon cancer.
Risk of experiencing bone fractures in the past 5 years
The proportion of history of bone fractures in the past 5 years was significantly lower in the intake group compared to non-intake group for women, with a significant reduction of risk for experiencing bone fractures by 16% (P = 0.04). The proportion of history of bone fractures in men was lower than that in women, and there was no significant difference between the intake and non-intake groups.
Igarashi et al. (1994) reported that a simultaneous administration of B. longum BB536 and milk calcium was more effective in improving the bone strength as compared to administration of calcium alone in rats. The present survey suggested the potential for B. longum BB536 in lowering the risk of bone fractures.
About BB536 and Morinaga
Bifidobacterium longum BB536 was isolated from human intestine and is one of the most thoroughly researched probiotic strains in the world. Morinaga has conducted research and development on BB536 for over 40 years, and achieved U.S. FDA-notified GRAS in 2009. Supported by over 110 published studies, BB536’s beneficial effects have been confirmed in such clinical areas as intestinal health, immunity, infection, and allergy.
Morinaga Milk Industry Co., Ltd. is the second largest dairy product company in Japan, founded in 1917 and employing 3,080 people. Morinaga has exhibited excellence in the field of technology and has offered not only dairy products but also other beneficial functional ingredients to the world for years. For more information, visit us at http://www.morinagamilk.co.jp/english/.
P. Bercik et al., The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication; Neurogastroenterol Motil. 23(12):1132-9 (2011)
S. Reddy and Abraham Rivenson, Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f] quinoline, a food mutagen; Cancer Research 53 : 3914-3918 (1993)
T.Odamaki et al., Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota; Anaerobe. 18(1)14-18 (2012)
M. Igarashi et al., Effect of Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rats; Bifidus 7 : 139-147 (1994)
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
HCL Technologies Powers Volvo Ocean Race 2017-1823.10.2017 13:02 | Pressemelding
The 2017-18 edition of the Volvo Ocean Race was flagged off at Alicante, Spain, with HCL Technologies as the strategic IT services provider. The leading global IT services company has provided end-to-end infrastructure support as well as connectivity between the Race Village and the Command Centre in Alicante further connecting them to 12 Host Cities on the race route globally. The world's longest and toughest professional sporting event began at Alicante and will finish eight months later at The Hague. At the flag-off, Jordi Neves, Chief Digital Officer, Volvo Ocean Race, said: “Over four decades, Volvo Ocean Race has drawn some of the greatest ever sailors. This edition of the race will be more digitally focused than before, with HCL as the strategic IT services provider. This edition is also special for us as we embark on a major Sustainability Program in partnership wi
CES Unveiled Paris Returns Tomorrow for Fifth Year with 70+ Exhibitors23.10.2017 13:00 | Pressemelding
Consumer Technology Association (CTA): WHAT: CES Unveiled Paris returns to Paris tomorrow, for its fifth consecutive year, hosting more than 70 exhibitors. More than 600 attendees are expected at the event which will unite French tech startups, top media, buyers and industry influencers around the latest tech innovation and provide a preview of CES® 2018. Schedule as follows:
Wipro Cited as a Leader in Everest Group PEAK Matrix™ for IT Security Services23.10.2017 12:59 | Pressemelding
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been recognized as a ‘Leader’ by Everest Group, a global independent consulting and research firm, in its report titled “IT Security Services- Market Trends and PEAK MatrixTM Assessment 2017: Security- the Biggest Digital Insecurity”. The report analyzed the capabilities of 17 leading global IT service providers on Everest Group’s PEAK Matrix. Wipro has been named as a Leader for its strong global delivery network with a transformational mind-set, and its ability to deliver high quality of services across regions and service segments, in terms of both execution and responsiveness. The report highlights the trends influencing the IT security services market, focusing on the increasing complexities, size and
ZeroStack Delivers Unified Multi-Cloud Application Development Platform Leveraging Existing Hardware Assets23.10.2017 12:00 | Pressemelding
ZeroStack, Inc., creators of the self-driving on-premises cloud, today announced that its cloud platform now runs on Nutanix HCI hardware, expanding choices for IT departments that want to empower their DevOps groups with a software-defined infrastructure that offers SaaS-delivered, multi-cloud operations. Developers can have a consistent platform no matter where they are located while reducing operational complexity and costs. Developers need a common platform to reduce costs and ensure efficient processes for software development, and budget-constrained IT departments want to gain maximum leverage out of existing hardware. ZeroStack’s Intelligent Cloud Platform is hardware independent, so it enables consistent processes regardless of the hardware used or where the developers access the infrastructure. As a result, developers can create secure private workspaces and build a per
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab23.10.2017 11:15 | Pressemelding
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer’s disease treatments. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005462/en/ Under the terms of the agreement Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta (Aβ) antibody for patients with Alzheimer’s disease (“AD”). The expanded agreement leverages each company’s respective geographic strengths for commercialization and adjusts the respective share of profits from potential sales of aducanumab. Biogen will receive 55
Open Letter from Mats Granryd, Director General, GSMA23.10.2017 11:01 | Pressemelding
Dear Ministers, As you are no doubt aware, European citizens and businesses rely on mobile networks to socialise, do business and access information everyday in every corner of every Member State of the Union. The social and economic activity that rides over this digital infrastructure drives economic growth, shapes future innovation and fosters more inclusive societies. As you prepare to convene at tomorrow’s Ministerial Council Meeting, I must express my grave concerns on the current state of discussions on the proposed European Electronic Communication Code (the Code). Although the European Union’s vision of a ‘Gigabit Society’, and recent discussions amongst the European Heads of State, demonstrate a strong ambition to recapture the region’s digital leadership and harness the full power of digital to drive growth, jobs and competitiveness, we do not see action foc
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom